GCM
KRYS icon

Graham Capital Management’s Krystal Biotech KRYS Stock Holding History

Graham Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,435
Closed -$335K – 1463
2025
Q2 		$335K Buy
2,435
+256
+12% +$37.6K 0.01% 959
2025
Q1 		$393K Buy
2,179
+97
+5% +$16.3K 0.01% 903
2024
Q4 		$326K Sell
2,082
-149
-7% -$26.4K ﹤0.01% 895
2024
Q3 		$406K Sell
2,231
-148
-6% -$28.5K 0.01% 695
2024
Q2 		$437K Buy
+2,379
New +$399K 0.01% 625
2023
Q4 		– Sell
-2,849
Closed -$330K – 1169
2023
Q3 		$330K Buy
+2,849
New +$348K 0.01% 691

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Graham Capital Management's KRYS Position: Q3 2025 in Review

Graham Capital Management sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 2,435 shares — an estimated $335K sold.

Graham Capital Management first reported a position in KRYS in Q3 2023 and held it in 6 quarters. The position peaked at $437K in Q2 2024. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

  • Graham Capital Management reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
  • Graham Capital Management sold 2,435 Krystal Biotech shares in Q3 2025, an estimated $335K.
  • Graham Capital Management first reported a position in Krystal Biotech in Q3 2023 and held it in 6 quarters.
  • Graham Capital Management's Krystal Biotech position peaked at $437K in Q2 2024.
  • 284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on Graham Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.